Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points We’re raising our top- and bottom-line outlook for RTX after yesterday’s impressive 2Q earnings report, and we’re reiterating our Overweight rating on the shares. Our target price rises ......
Key Points Q2’26 EPS and EBITDA beat on pricing strength; Q3’26 guidance below consensus Near-term commentary and guidance mixed We rate Dow Inc. shares Overweight with a 12-month target price ......
Key Points We’re raising our mid-term topline growth outlook for NOC (~1.5% on average) post the firm’s mixed 2Q results yesterday, and we’re reiterating our Overweight rating on the shares. ......
Key Points Inventory depletion, not demand destruction, may be setting the stage for a potential chemical market squeeze China’s broad-based destocking could fuel a global restocking cycle Consensus appears to ......
Key Points We’re modestly raising our top- and bottom-line forecast for BA post the release yesterday of 2Q order and deliveries data. We’re holding firm to our USD305 target price ......
Key Points Commodity chemical fundamentals improved despite weak equity performance. Above consensus for CE, LYB, and MEOH in Q2 Inventory depletion could trigger a 2003-style oil and petrochemical squeeze Positive ......